Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5609-5615

  Ikawa, Kazuro ^a,b   Nakashima, Akira ^a   Morikawa, Norifumi ^a   Ikeda, Kayo ^a   Murakami, Yoshiaki ^a   Ohge, Hiroki ^a   Derendorf, Hartmut ^b   Sueda, Taijiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIAPENEM; MEROPENEM;

AGED; ARTICLE; BACTERIUM ISOLATE; BILE; BILIARY TRACT INFECTION; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG TARGETING; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BILE; BILIARY TRACT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; THIENAMYCINS;

EID: 81555224260     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00497-11     Document Type: Article

References (27)

1. Bassetti, M., L. Nicolini, S. Esposito, E. Righi, and C. Viscoli. 2009. Current status of newer carbapenems. Curr. Med. Chem. 16:564-575.
2. Burman, L. A., I. Nilsson-Ehle, M. Hutchison, S. J. Haworth, and S. R. Norrby. 1991. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem. J. Antimicrob. Chemother. 27:219-224.
3. Condon, R. E., et al. 1997. Penetration of meropenem in plasma and abdominal tissues from patients undergoing intraabdominal surgery. Clin. Infect. Dis. 24(Suppl. 2):S181-S183. (Pubitemid 27130705)
4. Frei, C. R., N. P. Wiederhold, and D. S. Burgess. 2008. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic- pharmacodynamic models with Monte Carlo simulation. J. Antimicrob. Chemother. 61:621-628. (Pubitemid 351321137)
5. George, J., and J. Baillie. 2005. Contemporary management of biliary tract infections. Curr. Infect. Dis. Rep. 7:108-114.
6. Gilbert, D. N., R. C. Moellering, G. M. Eliopoulos, H. F. Chambers, and M. S. Saag. 2010. The Sanford guide to antimicrobial therapy, 40th ed., p. 15. Antimicrobial Therapy, Sperryville, VA.
7. Granai, F., H. L. Smart, and D. R. Triger. 1992. A study of the penetration of meropenem into bile using endoscopic retrograde cholangiography. J. Antimicrob. Chemother. 29:711-718.
8. Graziani, A. L., G. A. Gibson, and R. R. MacGregor. 1987. Biliary excretion of imipenem-cilastatin in hospitalized patients. Antimicrob. Agents Chemother. 31:1718-1721. (Pubitemid 17157632)
9. Hara, K., et al. 1999. Clinical evaluation of biapenem in various infectious diseases. Jpn. J. Antibiot. 52:629-660.
10. Ikawa, K., et al. 2010. Pharmacokinetic-pharmacodynamic target attainment analysis of meropenem in Japanese adult patients. J. Infect. Chemother. 16:25-32.
11. Ikawa, K., et al. 2008. Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: a dosing strategy. Chemotherapy 54:386-394.
12. Ikawa, K., et al. 2009. Pharmacokinetics and pharmacodynamics of biapenem in human cerebrospinal fluid. Int. J. Antimicrob. Agents 34:184-185.
13. Ikawa, K., et al. 2009. Penetrability of intravenous biapenem into the peritoneal fluid of laparotomy patients and the peritoneal pharmacodynamics against Gram-negative bacteria. J. Appl. Res. 9:107-112.
14. Kameda, K., et al. 2010. HPLC method for measuring meropenem and biapenem concentrations in human peritoneal fluid and bile: application to comparative pharmacokinetic investigations. J. Chromatogr. Sci. 48:406-411.
15. Karachalios, G., and K. Charalabopoulos. 2002. Biliary excretion of antimicrobial drugs. Chemotherapy 48:280-297. (Pubitemid 36407811)
16. Lehr, T., et al. 2009. A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam. Clin. Pharmacokinet. 48:529-542.
17. Mouton, J. W., M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55:601-607.
18. Nakashima, M., et al. 1993. Phase 1 study of L-627, biapenem, a new parenteral carbapenem antibiotic. Int. J. Clin. Pharmacol. Ther. Toxicol. 31:70-76. (Pubitemid 23088087)
19. Roberts, M. S., B. M. Magnusson, F. J. Burczynski, and M. Weiss. 2002. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin. Pharmacokinet. 41:751-790.
20. Soga, Y., et al. 2010. Peritoneal pharmacokinetics and pharmacodynamic target attainment of meropenem in patients undergoing abdominal surgery. J. Chemother. 22:98-102.
21. Tanaka, A., et al. 2007. Antimicrobial therapy for acute cholangitis: Tokyo guidelines. J. Hepatobiliary Pancreat. Surg. 14:59-67. (Pubitemid 46189143)
22. Tsumura, R., et al. 2008. The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients. J. Chemother. 20:615-621.
23. Westphal, J. F., and J. M. Brogard. 1999. Biliary tract infections: a guide to drug treatment. Drugs 57:81-91.
24. Westphal, J. F., et al. 1997. Assessment of biliary excretion of piperacillintazobactam in humans. Antimicrob. Agents Chemother. 41:1636-1640.
25. Yamaguchi, K., et al. 2007. Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006. Jpn. J. Antibiot. 60:344-377. (Pubitemid 351154892)
26. Yamaoka, K., Y. Tanigawara, T. Nakagawa, and T. Uno. 1981. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn. 4:879-885. (Pubitemid 12174128)
27. Zhanel, G. G., et al. 2007. Comparative review of the carbapenems. Drugs 67:1027-1052. (Pubitemid 46744477)